GO CHINA
& JAPAN
ONESTOP AGENCY
Rethinking health: Opportunities for German and European pharmaceutical and botanical products in Asia
China and Japan are among the world's most dynamic pharmaceutical and healthcare markets. In China, demand for innovative medicines, herbal products, and health solutions is growing rapidly, driven by an aging population and increasing health awareness. Japan, one of the world's largest pharmaceutical markets, boasts high purchasing power, stringent quality standards, and a strong tradition of natural and herbal medicine. European pharmaceutical companies, particularly those from Germany, benefit from the excellent reputation of Germany's herbal medicine tradition: quality, research expertise, and proven herbal active ingredients enjoy widespread trust. Alongside conventional active ingredients, herbal and holistic products are gaining increasing importance. Strategic market access requires an understanding of local regulations, cultural preferences, and the specific role of health trends in both countries. Targeting these markets effectively can lead to sustainable growth and new partnerships.
Build and expand your business in the growth markets of China and Japan
Entering the Chinese and Japanese markets requires far more than regulatory compliance. Successful products must be integrated into existing medical systems of thought, healthcare structures, and consumer habits. Tasly Germany's OneStop Agency offers in-depth strategic support for this process. Western phyto- and health products are not simply transferred one-to-one, but rather specifically adapted to local expectations – be it in terms of product form, application logic, communication style, or pricing structure. At the same time, Western quality and safety standards are leveraged as a differentiating factor. Through its network of industry partners, scientific institutions, and local market players, the OneStop Agency facilitates access to sustainable partnerships. The goal is not short-term market entry, but rather the long-term development of a robust market presence in two of the world's most important healthcare markets.
Benefiting together: Local expertise meets European innovation
Our long-standing presence in China gives us an invaluable advantage: As a subsidiary of Tasly Pharma (founded in 1994) headquartered in China, we understand local market mechanisms, regulatory requirements, and cultural nuances like no other. European partners benefit directly from this – whether launching traditional pharmaceuticals or innovative herbal products. We can efficiently manage processes from regulatory approval and distribution to marketing strategies, ensuring that products reach the market quickly and safely. Our parent company also has a direct presence in Japan. This allows us to combine a deep understanding of the high quality standards, regulatory requirements, and specific consumer preferences. For European pharmaceutical companies, this means a partner who not only builds bridges but actively fosters growth. Both sides benefit – European manufacturers from our local expertise and networks, and the markets from proven European innovations and the renowned German herbal medicine tradition.
